WO2013064672A3 - Oxazaphosphorines dosed one time for treating diseases - Google Patents

Oxazaphosphorines dosed one time for treating diseases Download PDF

Info

Publication number
WO2013064672A3
WO2013064672A3 PCT/EP2012/071772 EP2012071772W WO2013064672A3 WO 2013064672 A3 WO2013064672 A3 WO 2013064672A3 EP 2012071772 W EP2012071772 W EP 2012071772W WO 2013064672 A3 WO2013064672 A3 WO 2013064672A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxazaphosphorines
time
treating diseases
dosed
ido
Prior art date
Application number
PCT/EP2012/071772
Other languages
German (de)
French (fr)
Other versions
WO2013064672A2 (en
Inventor
Ulf Niemeyer
Jörg POHL
Original Assignee
Ulf Niemeyer
Pohl Joerg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulf Niemeyer, Pohl Joerg filed Critical Ulf Niemeyer
Publication of WO2013064672A2 publication Critical patent/WO2013064672A2/en
Publication of WO2013064672A3 publication Critical patent/WO2013064672A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to oxazaphosphorines of formula (I), wherein R1 and R2 are 2-chloroethyl or H and R3 is 2-sulfonatoethylthio or H, for treating diseases that are caused or maintained by the tolerogen indolamine-2,3-dioxygenase (IDO), wherein the oxazaphosphorines of formula (I) are administered one time in a dose of at most 0.3 mmol/m2 and thus act against the tolerogen IDO. The invention further relates to the use of said oxazaphosphorines to produce a medication for use in treating diseases that are caused or maintained by the activation of the expression of indolamine-2,3-dioxygenase (IDO), wherein the oxazaphosphorines of formula (I) are administered one time in a dose of at most 0.3 mmol/m2.
PCT/EP2012/071772 2011-11-03 2012-11-02 Oxazaphosphorines dosed one time for treating diseases WO2013064672A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011085695A DE102011085695A1 (en) 2011-11-03 2011-11-03 One-time dosed oxazaphosphorines for the treatment of diseases
DE102011085695.1 2011-11-03

Publications (2)

Publication Number Publication Date
WO2013064672A2 WO2013064672A2 (en) 2013-05-10
WO2013064672A3 true WO2013064672A3 (en) 2013-07-04

Family

ID=47143899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/071772 WO2013064672A2 (en) 2011-11-03 2012-11-02 Oxazaphosphorines dosed one time for treating diseases

Country Status (2)

Country Link
DE (1) DE102011085695A1 (en)
WO (1) WO2013064672A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052598A1 (en) * 1997-05-21 1998-11-26 Genentech, Inc. Novel administration of thrombopoietin
WO1999003976A2 (en) * 1997-07-21 1999-01-28 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
WO2003103389A2 (en) * 2002-06-10 2003-12-18 Avax Technologies Inc. Cryopreservation of haptenized tumor cells
US20070123518A1 (en) * 2003-10-01 2007-05-31 Epshtein Oleg I Product designed to protentiate the therapeutic effects and to enhance the action of medicinal preparations
US20080131495A1 (en) * 2004-04-01 2008-06-05 Biomira, Inc. Mucinous Glycoprotein (Muc-1) Vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
DE102004050111A1 (en) 2004-10-13 2006-04-27 Pohl, Jörg, Dr. New active substances (e.g. 1-methyl-DL-tryptophan) are indolamine-2,3-dioxygenase enzyme inhibitors useful for the treatment of curative diseases such as cancer, local immune tolerance and/or suppressions and arteriosclerosis
DE102005008797A1 (en) 2005-02-25 2006-09-07 Baxter International Inc., Deerfield Trofosfamide-containing film-coated tablets and process for their preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052598A1 (en) * 1997-05-21 1998-11-26 Genentech, Inc. Novel administration of thrombopoietin
WO1999003976A2 (en) * 1997-07-21 1999-01-28 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
WO2003103389A2 (en) * 2002-06-10 2003-12-18 Avax Technologies Inc. Cryopreservation of haptenized tumor cells
US20070123518A1 (en) * 2003-10-01 2007-05-31 Epshtein Oleg I Product designed to protentiate the therapeutic effects and to enhance the action of medicinal preparations
US20080131495A1 (en) * 2004-04-01 2008-06-05 Biomira, Inc. Mucinous Glycoprotein (Muc-1) Vaccine

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 12 May 1997 (1997-05-12), DRAGSTED N O ET AL: "[Survival in ovarian cancer treated in a gynecological department of a central hospital].", XP002690616, Database accession no. NLM9190729 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2006, SWIATONIOWSKI GRZEGORZ ET AL: "[Surprisingly positive effect of palliative CAP chemotherapy of bone-disseminated, undifferentiated carcinoma of unknown primary origin in patient with low performance status according to WHO].", XP002690615, Database accession no. NLM16969902 *
HOON D S B ET AL: "SUPPRESSOR CELL ACTIVITY IN A RANDOMIZED TRIAL OF PATIENTS RECEIVING ACTIVE SPECIFIC IMMUNOTHERAPY WITH MELANOMA CELL VACCINE AND LOW DOSAGES OF CYCLOPHOSPHAMIDE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 50, no. 17, 1 September 1990 (1990-09-01), pages 5358 - 5364, XP001179425, ISSN: 0008-5472 *
N J DAWSON: "THE SURFACE-AREA/BODY-WEIGHT RELATIONSHIP IN MICE", AUST. J. BIOL. SCI., 1967, 20, 1 January 1967 (1967-01-01), pages 687 - 690, XP055049943, Retrieved from the Internet <URL:http://www.publish.csiro.au/?act=view_file&file_id=BI9670687.pdf> [retrieved on 20130116] *
PRZEGLAD LEKARSKI 2006, vol. 63, no. 3, 2006, pages 166 - 168, ISSN: 0033-2240 *
R.E. ELMSLIE ET AL: "Metronomic Therapy with Cyclophosphamide and Piroxicam Effectively Delays Tumor Recurrence in Dogs with Incompletely Resected Soft Tissue Sarcomas", JOURNAL OF VETERINARY INTERNAL MEDICINE, vol. 22, no. 6, 1 November 2008 (2008-11-01), pages 1373 - 1379, XP055050184, ISSN: 0891-6640, DOI: 10.1111/j.1939-1676.2008.0179.x *
TAKASHI FUKUTOMI ET AL: "Adjuvant Six Cycles of High-Dose Adriamycin, Cyclophosphamide, Methotrexate, 5-Fluorouracil (ACMF) vs. 12 Cycles of low-Dose ACMF With Tamoxifen for Premenopausal, Node-Positive Breast Cancer Patients: Results of a Prospective Randomized Study", JOURNAL OF SURGICAL ONCOLOGY 60:242-246 (1995), 1 January 1995 (1995-01-01), pages 242 - 246, XP055049898, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1002/jso.2930600406/asset/2930600406_ftp.pdf?v=1&t=hc0grvl2&s=bc50ad3b38a052c7361effd6685bcc87aff19fd6> [retrieved on 20130116] *
UGESKRIFT FOR LAEGER 12 MAY 1997, vol. 159, no. 20, 12 May 1997 (1997-05-12), pages 3003 - 3009, ISSN: 0041-5782 *

Also Published As

Publication number Publication date
DE102011085695A1 (en) 2013-05-08
WO2013064672A2 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12016501204A1 (en) Syk inhibitors
MA33939B1 (en) 5-alkynyl-PYRIMIDINE
EA201201648A1 (en) SGC STIMULATORS
MX336381B (en) Boronates as arginase inhibitors.
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MX2009011473A (en) Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
UA115320C2 (en) Kinase inhibitors
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
MY163202A (en) Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201391486A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON&#39;S DISEASE
MX2015010354A (en) C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv.
MD20150048A2 (en) Pyrrolotriazinone derivatives as PI3K inhibitors
MX343160B (en) Treatment of diseases.
CR20200286A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer&#39;s disease
MX2013008056A (en) 1,4-oxazepines as bace1 and/or bace2 inhibitors.
MX2015004362A (en) Ketamine derivatives.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2013008340A (en) Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer.
MY178390A (en) Inhibitors of iap

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12783204

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12783204

Country of ref document: EP

Kind code of ref document: A2